These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 11207034)
1. Polymorphisms in the human paraoxonase (PON1) promoter. Brophy VH; Hastings MD; Clendenning JB; Richter RJ; Jarvik GP; Furlong CE Pharmacogenetics; 2001 Feb; 11(1):77-84. PubMed ID: 11207034 [TBL] [Abstract][Full Text] [Related]
2. Paraoxonase-1 promoter haplotypes and serum paraoxonase: a predominant role for polymorphic position - 107, implicating the Sp1 transcription factor. Deakin S; Leviev I; Brulhart-Meynet MC; James RW Biochem J; 2003 Jun; 372(Pt 2):643-9. PubMed ID: 12639220 [TBL] [Abstract][Full Text] [Related]
3. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Leviev I; James RW Arterioscler Thromb Vasc Biol; 2000 Feb; 20(2):516-21. PubMed ID: 10669651 [TBL] [Abstract][Full Text] [Related]
4. Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Brophy VH; Jampsa RL; Clendenning JB; McKinstry LA; Jarvik GP; Furlong CE Am J Hum Genet; 2001 Jun; 68(6):1428-36. PubMed ID: 11335891 [TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomic considerations of the paraoxonase polymorphisms. Furlong CE; Cole TB; Jarvik GP; Costa LG Pharmacogenomics; 2002 May; 3(3):341-8. PubMed ID: 12052142 [TBL] [Abstract][Full Text] [Related]
6. Roles of Sp1 and protein kinase C in regulation of human serum paraoxonase 1 (PON1) gene transcription in HepG2 cells. Osaki F; Ikeda Y; Suehiro T; Ota K; Tsuzura S; Arii K; Kumon Y; Hashimoto K Atherosclerosis; 2004 Oct; 176(2):279-87. PubMed ID: 15380450 [TBL] [Abstract][Full Text] [Related]
7. Human paraoxonase-1 gene expression by HepG2 cells is downregulated by interleukin-1beta and tumor necrosis factor-alpha, but is upregulated by interleukin-6. Kumon Y; Suehiro T; Ikeda Y; Hashimoto K Life Sci; 2003 Oct; 73(22):2807-15. PubMed ID: 14511766 [TBL] [Abstract][Full Text] [Related]
8. Human serum paraoxonase. Mackness B; Durrington PN; Mackness MI Gen Pharmacol; 1998 Sep; 31(3):329-36. PubMed ID: 9703197 [TBL] [Abstract][Full Text] [Related]
9. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. Mackness B; Mackness MI; Arrol S; Turkie W; Durrington PN FEBS Lett; 1998 Feb; 423(1):57-60. PubMed ID: 9506841 [TBL] [Abstract][Full Text] [Related]
10. Serum paraoxonase-1 (PON1) activities (PONase/AREase) and polymorphisms in patients with type 2 diabetes mellitus in a North-West Indian population. Gupta N; Binukumar BK; Singh S; Sunkaria A; Kandimalla R; Bhansali A; Gill KD Gene; 2011 Nov; 487(1):88-95. PubMed ID: 21803130 [TBL] [Abstract][Full Text] [Related]
11. Polymorphisms of paraoxonase (PON1) and their significance in clinical toxicology of organophosphates. Costa LG; Cole TB; Furlong CE J Toxicol Clin Toxicol; 2003; 41(1):37-45. PubMed ID: 12645966 [TBL] [Abstract][Full Text] [Related]
12. Paraoxonase (PON 1) as a biomarker of susceptibility for organophosphate toxicity. Costa LG; Richter RJ; Li WF; Cole T; Guizzetti M; Furlong CE Biomarkers; 2003; 8(1):1-12. PubMed ID: 12519632 [TBL] [Abstract][Full Text] [Related]
13. Role of protein kinase C in pitavastatin-induced human paraoxonase I expression in Huh7 cells. Arii K; Suehiro T; Ikeda Y; Kumon Y; Inoue M; Inada S; Takata H; Ishibashi A; Hashimoto K; Terada Y Metabolism; 2010 Sep; 59(9):1287-93. PubMed ID: 20092859 [TBL] [Abstract][Full Text] [Related]
14. Analysis of paraoxonase (PON1) L55M status requires both genotype and phenotype. Brophy VH; Jarvik GP; Richter RJ; Rozek LS; Schellenberg GD; Furlong CE Pharmacogenetics; 2000 Jul; 10(5):453-60. PubMed ID: 10898114 [TBL] [Abstract][Full Text] [Related]
15. Association between serum paraoxonase (PON1) gene promoter T(-107)C polymorphism, PON1 activity and HDL levels in healthy Sicilian octogenarians. Campo S; Sardo MA; Trimarchi G; Bonaiuto M; Fontana L; Castaldo M; Bonaiuto A; Saitta C; Bitto A; Manduca B; Riggio S; Saitta A Exp Gerontol; 2004 Jul; 39(7):1089-94. PubMed ID: 15236768 [TBL] [Abstract][Full Text] [Related]
16. Effects of PON polymorphisms and haplotypes on molecular phenotype in Mexican-American mothers and children. Huen K; Barcellos L; Beckman K; Rose S; Eskenazi B; Holland N Environ Mol Mutagen; 2011 Mar; 52(2):105-16. PubMed ID: 20839225 [TBL] [Abstract][Full Text] [Related]
17. Rabbits possess a serum paraoxonase polymorphism similar to the human Q192R. Watson CE; Draganov DI; Billecke SS; Bisgaier CL; La Du BN Pharmacogenetics; 2001 Mar; 11(2):123-34. PubMed ID: 11266077 [TBL] [Abstract][Full Text] [Related]
18. Paraoxonase-1 genetic polymorphisms and susceptibility to DNA damage in workers occupationally exposed to organophosphate pesticides. Singh S; Kumar V; Thakur S; Banerjee BD; Rautela RS; Grover SS; Rawat DS; Pasha ST; Jain SK; Ichhpujani RL; Rai A Toxicol Appl Pharmacol; 2011 Apr; 252(2):130-7. PubMed ID: 21291901 [TBL] [Abstract][Full Text] [Related]
19. Paraoxonase promoter polymorphism T(-107)C and relative paraoxonase deficiency as determinants of risk of coronary artery disease. Leviev I; Righetti A; James RW J Mol Med (Berl); 2001 Aug; 79(8):457-63. PubMed ID: 11511976 [TBL] [Abstract][Full Text] [Related]